10 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self-reported by individual patients
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
endpoint was the proportion of patients who achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self
Analyst Expectations For Rhythm Pharmaceuticals's Future
RYTM
26 Apr 24
(NASDAQ:RYTM) in the last three months.
Summarizing their recent assessments, the table
bk77swx
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
9ghtiptjjd2e 3ze6zpv37
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
guddz7oldi21lmvq859yqv46jih0ig030zfkw
RYTM
10 Apr 24
quarter vary from bullish to bearish, as provided by 5 analysts.
Summarizing their recent assessments, the table below illustrates the evolving
9c3zdie3vfwnjknpgiwe5b89qhpc0hzrd2s cfbwgb1p6gtmbblyshuxpa1x
RYTM
11 Mar 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
6cnwaim58vwwwe8qa0yqggchla8c1vj479et
RYTM
6 Mar 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe
- Prev
- 1
- Next